Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jingangteng is a traditional Chinese medicine (TCM) botanical extract derived from the rhizome of *Smilax china* L. (Chinaroot Greenbrier). It is primarily indicated for the treatment of gynecological inflammatory diseases, including chronic pelvic inflammatory disease (PID), adnexitis, and inflammatory adnexal masses. Developed and manufactured by Beijing Foyou Pharmaceutical as a soft capsule formulation, it functions by clearing heat, detoxifying, and resolving dampness according to TCM principles. Pharmacological studies suggest it possesses anti-inflammatory, analgesic, and immunomodulatory properties, likely mediated through the inhibition of inflammatory mediators and the modulation of the immune response in the pelvic cavity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jingangteng.